Business · 20/02/2026Updated: 10/16/2026 · 1 min read
Prospective Grant of an Exclusive Patent License: In Vivo Manufactured Anti-CD19 Chimeric Antigen Receptor (CAR) Products for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases
Summary
The US Department of Health and Human Services, National Institutes of Health published a correction notice in the Federal Register on August 5, 2025, regarding a patent license for autoimmune disease treatment.